Subscribe

What are you looking for?

Main Menu

明報新聞網

和黃醫藥在中美啟動第二款抗體靶向偶聯藥物臨床試驗

Future Wealths
Future Wealths
4 3 月, 2026
One Min Read
4 Views
0 Comments
和黃醫藥（中國）（0013 ）宣布，在中國和美國啟動第二款抗體靶向偶聯藥物（「ATTC」）HMPL-A580，用於治療不可切除的晚期或轉移性實體瘤的I/IIa期臨牀試驗。首名患者已於3月4日於接受首次給藥治療。

原文: https://finance.mingpao.com/fin/instantf/20260304/1772618643355/%E5%92%8C%E9%BB%83%E9%86%AB%E8%97%A5%E5%9C%A8%E4%B8%AD%E7%BE%8E%E5%95%9F%E5%8B%95%E7%AC%AC%E4%BA%8C%E6%AC%BE%E6%8A%97%E9%AB%94%E9%9D%B6%E5%90%91%E5%81%B6%E8%81%AF%E8%97%A5%E7%89%A9%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A9%97%22%20target=%22blank

Last Update: 4 3 月, 2026

Please share this article if you like it!

Link Copied!
Future Wealths
Written By

Future Wealths

Other Articles

Related Posts

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept